ORIC-533 — Investigational Agent
Other · Phase 1 · ORIC Pharmaceuticals
Mechanism of Action
Oral small-molecule inhibitor of CD73 (ecto-5'-nucleotidase), blocking generation of immunosuppressive extracellular adenosine in the myeloma bone-marrow microenvironment to restore T-cell and NK-cell antitumor function.
Investigational Indications
- Relapsed/refractory multiple myeloma